Superworth

Erasca EPS ERAS

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
−$0.95
Latest quarter, Q2 FY26
−$0.14
Fiscal year 2025
−$0.44

Erasca's earnings per share was −$0.95 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.14.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.44n/a
FY2024−$0.74n/a
FY2023−$0.83n/a
FY2022−$1.96n/a
FY2021−$2.73n/a
FY2020−$4.78n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.14n/a−$0.95
Q1 FY26−$0.60n/a−$0.93
Q4 FY25−$0.10n/a−$0.44
Q3 FY25−$0.11n/a−$0.45
Q2 FY25−$0.12n/a−$0.45
Q1 FY25−$0.11n/a−$0.62
Q4 FY24−$0.11n/a−$0.74
Q3 FY24−$0.11n/a−$0.83
Q2 FY24−$0.29n/a−$0.92
Q1 FY24−$0.23n/a−$0.84
Q4 FY23−$0.20n/a−$0.83
Q3 FY23−$0.20n/a−$1.69

Against its peers

Companies in Drug Manufacturers - General nearest Erasca's size, closest first, today.

CompanyEPS, 12 monthsGrowth
ERASErasca−$0.95
KNSAKiniksa Pharmaceuticals International$0.97+2325% a year
LGNDLigand Pharmaceuticals$9.40
INDVIndivior Pharmaceuticals$2.78+227% a year
ARQTArcutis Biotherapeutics$0.22
AMRXAmneal Pharmaceuticals$0.49+4800% a year
LQDALiquidia$1.39
OGNOrganon$0.77−71% a year
ALKSAlkermes plc.$0.38−82% a year
TGTXTG Therapeutics$2.74+641% a year
PTGXProtagonist Therapeutics$1.03+47% a year
Peer median$1.00

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Erasca

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.